Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves
social cognition, psychotic symptoms and social functioning in schizophrenia.
Participants: 80 adults with schizophrenia or schizoaffective disorder for at least one year.
Procedures (methods): Oxytocin or placebo will be administered twice daily in an intranasal
spray for 12 weeks. Before, during and at the end of the trial, each subject will undergo
psychiatric symptom ratings and tests of mental abilities used in social functioning,
cognition, and social competence.